These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35450742)

  • 1. Therapeutic efficacy and cognitive adverse events of overactive bladder medication in patients with central nervous system Disorders-A cohort study.
    Chen SF; Chuang YC; Wang CC; Liao CH; Kuo HC
    J Formos Med Assoc; 2022 Oct; 121(10):2101-2108. PubMed ID: 35450742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).
    Drake MJ; Chapple C; Esen AA; Athanasiou S; Cambronero J; Mitcheson D; Herschorn S; Saleem T; Huang M; Siddiqui E; Stölzel M; Herholdt C; MacDiarmid S;
    Eur Urol; 2016 Jul; 70(1):136-145. PubMed ID: 26965560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II).
    Gratzke C; van Maanen R; Chapple C; Abrams P; Herschorn S; Robinson D; Ridder A; Stoelzel M; Paireddy A; Yoon SJ; Al-Shukri S; Rechberger T; Mueller ER
    Eur Urol; 2018 Oct; 74(4):501-509. PubMed ID: 29866467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).
    Herschorn S; Chapple CR; Abrams P; Arlandis S; Mitcheson D; Lee KS; Ridder A; Stoelzel M; Paireddy A; van Maanen R; Robinson D
    BJU Int; 2017 Oct; 120(4):562-575. PubMed ID: 28418102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
    Chapple CR; Cruz F; Cardozo L; Staskin D; Herschorn S; Choudhury N; Stoelzel M; Heesakkers J; Siddiqui E
    Eur Urol; 2020 Jan; 77(1):119-128. PubMed ID: 31635815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder.
    Wang J; Zhou Z; Cui Y; Li Y; Yuan H; Gao Z; Zhu Z; Wu J
    Neurourol Urodyn; 2019 Jan; 38(1):22-30. PubMed ID: 30350884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study.
    Gibson W; MacDiarmid S; Huang M; Siddiqui E; Stölzel M; Choudhury N; Drake MJ
    Eur Urol Focus; 2017 Dec; 3(6):629-638. PubMed ID: 28916436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of treatment with mirabegron compared with solifenacin in the management of overactive bladder syndrome: A retrospective analysis.
    Schiavi MC; Faiano P; D'Oria O; Zullo MA; Muzii L; Benedetti Panici P
    J Obstet Gynaecol Res; 2018 Mar; 44(3):524-531. PubMed ID: 29271106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic efficacy of low-dose (25 mg) mirabegron therapy for patients with mild to moderate overactive bladder symptoms due to central nervous system diseases.
    Chen SF; Kuo HC
    Low Urin Tract Symptoms; 2019 Apr; 11(2):O53-O58. PubMed ID: 29380517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mirabegron Versus Solifenacin in Multiple Sclerosis Patients With Overactive Bladder Symptoms: A Prospective Comparative Nonrandomized Study.
    Brucker BM; Jericevic D; Rude T; Enemchukwu E; Pape D; Rosenblum N; Charlson ER; Zhovtis-Ryerson L; Howard J; Krupp L; Peyronnet B
    Urology; 2020 Nov; 145():94-99. PubMed ID: 32822687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Patterns with Mirabegron and Antimuscarinics for Overactive Bladder: A Prospective, Registry Study in Taiwan and South Korea (FAITH).
    Oh SJ; Cho ST; Kuo HC; Chou EC; Hsu YC; Lee KS; Hadi F; Song Y; Sumarsono B
    Adv Ther; 2024 Apr; 41(4):1652-1671. PubMed ID: 38430402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study.
    Mueller ER; van Maanen R; Chapple C; Abrams P; Herschorn S; Robinson D; Stoelzel M; Yoon SJ; Al-Shukri S; Rechberger T; Gratzke C
    Neurourol Urodyn; 2019 Feb; 38(2):779-792. PubMed ID: 30644570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.
    Kelleher C; Hakimi Z; Zur R; Siddiqui E; Maman K; Aballéa S; Nazir J; Chapple C
    Eur Urol; 2018 Sep; 74(3):324-333. PubMed ID: 29699858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    Int J Urol; 2019 Mar; 26(3):342-352. PubMed ID: 30548692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mirabegron versus Solifenacin in Children with Overactive Bladder: Prospective Randomized Single-Blind Controlled Trial.
    Soliman MG; El-Abd S; El-Gamal OM; Raheem AA; Abou-Ramadan AR; El-Abd AS
    Urol Int; 2021; 105(11-12):1011-1017. PubMed ID: 34010843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.
    Perk S; Wielage RC; Campbell NL; Klein TM; Perkins A; Posta LM; Yuran T; Klein RW; Ng DB
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1072-84. PubMed ID: 27579830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients.
    Robinson D; Kelleher C; Staskin D; Mueller ER; Falconer C; Wang J; Ridder A; Stoelzel M; Paireddy A; van Maanen R; Hakimi Z; Herschorn S
    Neurourol Urodyn; 2018 Jan; 37(1):394-406. PubMed ID: 28704584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR).
    Griebling TL; Campbell NL; Mangel J; Staskin D; Herschorn S; Elsouda D; Schermer CR
    BMC Geriatr; 2020 Mar; 20(1):109. PubMed ID: 32183741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.